Duration and determinants of Chagas latency: an etiology and risk systematic review protocol.


Journal

JBI database of systematic reviews and implementation reports
ISSN: 2202-4433
Titre abrégé: JBI Database System Rev Implement Rep
Pays: Australia
ID NLM: 101648258

Informations de publication

Date de publication:
Oct 2019
Historique:
pubmed: 25 7 2019
medline: 21 10 2020
entrez: 24 7 2019
Statut: ppublish

Résumé

The objective of this systematic review is to explore and discuss the latency duration among asymptomatic people with chronic Chagas disease. Studies estimate the latency period of Chagas disease to be approximately 10-30 years. However, new findings may indicate that this latency period is shorter and depends on the presence of clinical factors. This systematic review protocol will explore the duration and factors affecting this latency period to inform treatment, with the potential of improving outcomes. Eligible studies will include asymptomatic people with indeterminate Chagas disease confirmed through positive serologic testing and the absence of structural cardiomyopathy with no heart failure symptoms and normal electrocardiography results. Studies that involve a longitudinal observation period of participants will be considered. This period must start from the acute acquisition of the infection or an already established indeterminate form of the disease until the development of a primary or secondary cardiac outcome. The following electronic databases will be searched: MEDLINE, Embase, Cochrane Library, Web of Science Core Collection and LILACS. The search will include the following concepts: Chagas disease, latency duration and determinants of the Chagas latency period. The languages will be restricted to English, Spanish and Portuguese. Two reviewers will review the selected studies for methodological quality using critical appraisal tools and conduct data extraction. Studies will, where possible, be pooled in a statistical meta-analysis. All data will be presented and synthesized through tables, summaries, figures and charts. PROSPERO CRD42019118019.

Identifiants

pubmed: 31335560
doi: 10.11124/JBISRIR-D-18-00018
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2122-2128

Auteurs

Andrés F Henao-Martínez (AF)

Division of Infectious Diseases, School of Medicine, University of Colorado Denver, Aurora, USA.

Sindhu Chadalawada (S)

NRI General Hospital, Mangalagiri, India.

Wilmer E Villamil-Gomez (WE)

Departamento de Infectología, Hospital Universitario de Sincelejo, Sincelejo, Colombia.

Kristen DeSanto (K)

Health Sciences Library, University of Colorado Denver, Aurora, USA.

Anis Rassi (A)

Division of Cardiology, Anis Rassi Hospital, Goiânia, Brazil.

Carlos Franco-Paredes (C)

Division of Infectious Diseases, School of Medicine, University of Colorado Denver, Aurora, USA.
Hospital Infantil de México - Federico Gómez, México City, México.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH